Purpose: Stereotactic body radiation therapy (SBRT) is the standard of care for medically inoperable patients with early-stage NSCLC. However, NSCLC is composed of several histological subtypes and the impact of this heterogeneity on SBRT treatments has yet to be established.
Results: Overall, 72 patients had a local failure, with a cumulative incidence of local failure at 3 years of 11.8%. On univariate analysis, squamous histological subtype, younger age, fewer medical comorbidities, higher body mass index, higher positron emission tomography standardized uptake value, central tumors, and lower radiation dose were associated with an increased risk for local failure. On multivariable analysis, squamous histological subtype (hazard ratio ¼ 2.4 p ¼ 0.008) was the strongest predictor of local failure. Patients with squamous cancers fail SBRT at a significantly higher rate than do those with adenocarcinomas or NSCLC not otherwise specified, with 3-year cumulative rates of local failure of 18.9% (95% confidence interval [CI]: 12.7-25.1), 8 .7% (95% CI: 4.6-12.8), and 4.1% (95% CI: 0-9.6), respectively.
Conclusion:
Our results demonstrate an increased rate of local failure in patients with squamous cell carcinoma. Standard approaches for radiotherapy that demonstrate efficacy for a population may not achieve optimal results for individual patients. Establishing the differential dose effect of SBRT across histological groups is likely to improve efficacy and inform ongoing and future studies that aim to expand indications for SBRT.
Introduction
Clinical outcomes after surgery for patients with early-stage NSCLC are favorable, with 5-year survival rates ranging from 60% to 80%. 1 However, high rates of comorbid disease that could result in significant perioperative morbidity and affect long-term quality of life often disqualify many patients from surgery. In this milieu, noninvasive treatments such as stereotactic body radiotherapy (SBRT) to the lung were developed and expanded. To date, several prospective phase II trials using SBRT have been conducted in medically inoperable patients with excellent results, specifically, with 2-to 3-year local tumor control rates between 93% and 98%. [2] [3] [4] These successes have established SBRT as the standard of care in medically inoperable patients, and studies have begun to explore a role for SBRT in healthier patients with early-stage NSCLC. [5] [6] [7] [8] [9] [10] The use of SBRT for NSCLC has been optimized by the identification of tumor-and treatment-related factors that predict failure, including larger tumor size and lower radiation doses. [11] [12] [13] [14] However, whether groups within NSCLC are more or less likely to respond to treatments remains unclear. NSCLCs are characterized by substantial genetic diversity, and the optimal therapeutic approach is likely to vary depending on the genetic features of individual cancers. 15, 16 Indeed, the stratification of patients with NSCLC into more homogenous populations has resulted in a greater likelihood of response to specific agents. [17] [18] [19] [20] [21] [22] In the same manner, histological and molecular profiling of tumors may reveal subpopulations that are more or less likely to achieve local control after SBRT. Elucidating the interaction between radiation dose and NSCLC subtypes is critical for SBRT's optimization for indications beyond its current role in the treatment of medically inoperable patients with early-stage disease.
NSCLC is composed of two predominant histological subtypes, adenocarcinoma (w50%) and squamous cell carcinoma (SqCC) (w30%). 23 Histological characterization separates NSCLC into more homogeneous subtypes, 24 and there are important differences in the genetic and microenvironments of tumors from glandular origin (adenocarcinomas) and those of tumors with squamous differentiation. 15, 16, 25 Therefore, we posited that the histological subtype of lung cancer may affect the efficacy of SBRT. Herein, we used competing risk analysis to identify tumor and treatment factors that are predictive of local failure after SBRT.
Material and Methods

Patients
From an institutional review board-approved database of 1084 patients treated with lung SBRT from 2003 to 2015, we included patients with clinical stages T1N0M0 to T3N0M0 (seventh edition of American Joint Committee on Cancer staging) lung cancer and excluded patients with tumors that invaded the chest wall, synchronous primary tumors, and cases treated with the intent to salvage recurrent tumor after prior radiotherapy (RT) or surgery. Patients were treated on the basis of either a pathologic or radiographic diagnosis. A diagnosis of lung cancer was confirmed by histological examination of biopsy specimens for 69.8% of the patients studied. A general surgical pathologist or a pulmonary pathologist diagnosed cases from 2003 to July 2014. A staff pulmonary pathologist classified all lung cancer cases after July 2014. The World Health Organization classification system was used from 2003 to 2011. 26, 27 After 2011, the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system was used. 28 In most cases, a diagnosis of adenocarcinoma and SqCC was made solely on the basis of morphologic criteria. A histological or immunohistochemical staining panel was used to better define the diagnosis if the morphology was not distinctly that of SqCC or adenocarcinoma. In some cases, this resulted in diagnoses of NSCLC-favor adenocarcinoma or NSCLC-favor SqCC. These cases were grouped with their respective "favored" diagnosis. NSCLC not otherwise specified (NOS) was reserved for cases with strong, concurrent features of both adenocarcinoma and SqCC and cases without any definitive morphologic or immunohistochemical features of either adenocarcinoma or SqCC. Cases of large cell carcinoma before 2011 were reclassified as NSCLC NOS for consistency with the current terminology.
In 30.1% of patients who did not have a confirmed pathologic diagnosis (n ¼ 223), an attempt at a biopsy did not result in confirmation of malignant disease in 39% of cases (n ¼ 87 [11.8% of the overall population]). A radiographic diagnosis was established in cases in which a biopsy was contraindicated or was nondiagnostic. The criteria for a radiographic diagnosis included serial growth of a single lesion on computed tomography (CT) scans and a positron emission tomography (PET) standardized uptake value (SUV) that exceeded 3.0.
In all cases, an experienced thoracic surgeon and/or pulmonologist established medical inoperability. For each patient, the Charlson comorbidity index (CCI) was documented to assess comorbid illness, and baseline pulmonary function testing results were obtained. All patients were staged using a CT scan of the chest; PET/ CT and imaging of the brain (magnetic resonance imaging or CT) were used when clinically indicated. In cases in which imaging revealed mediastinal or hilar lymph nodes enlarged by accepted radiographic criteria or in which the standardized uptake value (SUV) exceeded a value of 3.0 on PET, pathologic mediastinal evaluation with endobronchial ultrasound was requested. 29 The use of chemotherapy after SBRT in patients considered at risk for distant failure was not routinely recommended given patient comorbidities. A small fraction of patients (8.8%) did receive chemotherapy at the discretion of the multidisciplinary treatment team.
Treatment
Our institutional approach for lung SBRT consists of immobilization in a Bodyfix vacuum system with abdominal compression (Elekta, Stockholm, Sweden) to restrict breathing motion, which is evaluated by fluoroscopy. 30 In cases in which motion could not be adequately restricted to less than 1 cm, the Active Breathing Coordinator device (Elekta, Stockholm, Sweden) was used. Tumors within a 2-cm expansion of the tracheobronchial tree were categorized as central. 31 Our institutional SBRT approach used a risk-adapted method. 32 Initially, all patients received 50 Gy in five fractions. When the RTOG 0236 trial commenced, we elected to treat eligible patients with peripheral tumors to 60 Gy in three fractions as per protocol and continued to treat central tumors to 50 Gy in five fractions. In total, 70.8% of all patients analyzed received 50 Gy in five fractions or 60 Gy in three fractions (45.3% and 25.5%, respectively). Alternative fractionations (30 All treatment plans were normalized to either the dose at the isocenter or the maximum point dose. The dose was prescribed to an isodose line between 60% and 90% so that the planning target volume (PTV) received at least 95% coverage and the minimal dose to the PTV (D99) was 90% of the prescription. Heterogeneity correction was applied in dose calculations except in dose schemes of 60 Gy in three fractions and 30 Gy in a single fraction; these plans were calculated by assuming homogeneous density within the patient. Patients were treated using a Novalis Platform (BrainLab, Munich, Germany) or NovalisTX radiosurgery system (Varian Medical Systems, Palo Alto, CA) using either step and shoot intensity-modulated RT, dynamic arc, or (very rarely) a volumetric arc therapy technique. Daily image guidance was performed with an orthogonal kilovoltage imaging (ExacTrac, BrainLab, Munich, Germany) with the addition of cone beam CT image guidance after 2011.
End Points
Local failure was defined as radiographic progression with or without positive biopsy results within 1 cm of the PTV to maintain a consistent definition of local/ marginal failure in clinical trials of SBRT. 3, 4, 33 One or more CT scans, followed by at least one PET/CT scan, determined radiographic progression. In cases in which PET/CT revealed a value less than that determined by the initial pretreatment PET/CT scan, another PET/CT scan was obtained. A maximum SUV exceeding the value determined by the initial pretreatment PET scan or serial increases in SUV on the posttreatment PET scan was considered a local failure. If PET/CT findings were consistent with failure, a biopsy was requested. A diagnosis of recurrent disease was confirmed histologically in 40.3% of the patients with local failure. All other patients were either medically unfit or unwilling to undergo a biopsy, or the lesion was deemed to be inaccessible by a staff radiologist and/or pulmonologist. In these cases, a diagnosis of recurrence was made on the basis of radiographic progression alone. PET/CTbased failures within the same lobe of the lung but more than 1 cm from the PTV of the initial treatment site were defined as lobar failure and were not considered in this analysis.
Statistical Analysis
Patients were grouped into four categories by tumor type: adenocarcinoma, SqCC, unknown, and NSCLC NOS. The unknown group included patients who did not undergo a tissue biopsy and those with a nondiagnostic biopsy result. The NSCLC NOS group included patients with large cell carcinoma (before 2011) and NSCLC NOS. Prescription radiation dose was adjusted for the number of fractions of radiation by calculating the biological equivalent dose (BED) with a standard a/b ratio of 10. BED RT dose was modeled as a categorical variable given its skewed distribution of prescription doses. Length of follow-up was determined from end date of SBRT, and patients who had not died were censored at the time of last chest imaging. Confidence intervals of the proportions were calculated by the Clopper and Pearson exact test. Confidence intervals of the median times to local failure were calculated by quantile estimates of the binomial distribution. Death without evidence of local failure was treated as a competing event, and Fine and Gray regression modeling was used to examine potential predictors of local failure. Age at the time of RT, sex, body mass index (BMI), current smoker status, CCI, PET/CT (SUV), tumor size, biologically effective dose, and histological categories were subjected to univariate analyses. Variables with a p value less than 0.1 were included in a multivariable model. Cumulative incidence curves (CICs) for local failure were estimated using the competing risk method, and Gray's test was used to determine significance between CICs. 34 Actuarial analysis was used to estimate rates of overall survival (OS) and the KaplanMeier method was used to generate OS curves. Statistical analysis was performed using SAS version 9.4 (SAS Inc., Cary, NC) and R 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). 35 
Results
Patient Characteristics
A total of 740 patients met our eligibility criteria. The median survival time for the group as a whole was 30 Fig. 1) . Adenocarcinoma, SqCC, unknown, and NSCLC NOS represented 32%, 29%, 30%, and 8% of the overall population, respectively (Table 1) . Patients were well balanced for patient age, sex, BMI, performance status, length of follow-up, and RT dose. Only nine patients (1.2%) did not undergo PET staging; one of these patients underwent mediastinal staging by endobronchial ultrasound. Patients with SqCC and those in the unknown group consumed more tobacco in terms of pack-years (p ¼ 0.019), and patients in the unknown group had a higher CCI (p ¼ 0.041). Patients with SqCC were more likely to have tumors of larger size (p < 0.001) and with higher PET SUV (p < 0.001). The median follow-up overall was 15. 
Tumor Control and Patterns of Recurrence
A total of 72 local failures were identified, with a cumulative incidence of local failure at 3 years of 11.8% (95% CI: 9.1-14.5) in the overall population. Of those local failures, 90.3% were observed to occur within 25.1 months of initial treatment (Fig. 1A) . The median times to local failure for SqCCs and adenocarcinomas in months were 14.9 (95% CI:11.4-17.2) and 18.9 (95% CI: 11.9-20.1), respectively (Fig. 1B) . The proportions of local failure for patients with SqCC, adenocarcinoma, unknown, and NOS NSCLC were 15.3% (95% CI: 10.8-20.9), 7.4% (95% CI: 4.4-11.4), 8.5% (95% CI: 5.2-13.0), and 3.4% (95% CI: 0.004-1.7), respectively. The 1-, 2-, and 3-year actuarial rates of local failure for the group as a whole were 4.2%, 14.6%, and 16%, respectively. Of patients with local failure, 54.2% (95% CI: 42.0-65.9) experienced a nodal or distant metastasis, whereas 21.1% (95% CI: 18.1-24.4) of patients with local control experienced nodal or distant failure. The increased rate of nodal or distant metastasis associated with local failure did not vary on the basis of histological category (Supplementary Table 1 ). Taken together, SqCCs had a higher proportion of local failure than other lung cancer subtypes and the rate of nodal or distant metastases was significantly higher in patients with a local failure than in those with no evidence of local failure, suggesting that local failure is associated with nodal and/or distant recurrence.
Predictive Factors
On univariate competing risk analysis, we demonstrated that squamous histological subtype, younger age, fewer medical comorbidities, higher BMI, higher PET SUV, central tumors, and lower radiation dose were associated with an increased risk for local failure (Table 2) . On multivariable analysis, squamous histological subtype (hazard ratio [HR] ¼ 2.4, 95% CI: 1.3-4.5, p ¼ 0.008) was the strongest predictor of local failure (Table 3) . Lower radiation dose (HR ¼ 0.99, p ¼ 0.008) and higher BMI (HR ¼ 1.07, p < 0.001) remained significantly associated with local failure. Estimated CICs for death and local failure for each lung cancer histological subtype are shown in Figure 2 . Gray's test for equality across histological groups was highly significant for local failure (p ¼ 0.002). Patients with squamous cancers fail SBRT at a significantly higher rate than do those with adenocarcinomas or NSCLC NOS, with 3-year cumulative incidences of local failure of 18.9% (95% CI: 12.7-25.1), 8.7% (95% CI: 4.6-12.8), and 4.1% (95% CI: 0-9.6), respectively. Gray's test for equality across the groups was not statistically significant for death (p ¼ 0.07), although the probability of death appeared to trend higher in the NSCLC NOS group.
We plotted CICs for categories of radiation dose to assess the role of dose in local failure and generally observed a directly proportional increase in local control as a function of BED dose category (Fig. 2) . Although patients treated to a BED of 149.6 Gy, which corresponded to a single fraction of SBRT at a dose of 34 Gy, a Three patients with stage T3 disease were excluded from this analysis. HR, hazard ratio; 95% L, lower limit of 95% confidence interval; 95% U, upper limit of 95% confidence interval; BMI, body mass index; CCI, Charlson comorbidity index; PET, positron emission tomography; SUV, standardized uptake value; CT, computed tomography; SqCC, squamous cell carcinoma; Adeno, adenocarcinoma; NOS, not otherwise specified; BED, biologically effective dose.
fell below the trend line, they represented a small number of the patients treated (n ¼ 46). The two most common schedules used institutionally were 50 Gy in five fractions and 60 Gy in three fractions, or a BED of 100 and 180 Gy, respectively. To assess the impact of dose on local control between histological categories, we compared the CICs of adenocarcinomas and SqCCs within the two dose subgroups (100 Gy and 180 Gy BED) (Fig. 3 ). Gray's test for equality between the two histological groups was not statistically significant for local failure in the 180-Gy BED group (p ¼ 0.33), but it was significant in the 100-Gy BED group (p ¼ 0.021). The 3-year cumulative incidence of local failure for patients treated to a lower dose of 100 Table 2) . Within the T2 100-Gy BED subgroup, SqCCs were more likely to fail than were adenocarcinomas (HR ¼ 10.3, p ¼ 0.02). Taken together, these results indicate that SqCCs are significantly more likely to fail than are adenocarcinomas at the frequently used BED of 100 Gy and that the inferior local control rate is not explained solely by the larger tumor size of SqCCs.
Discussion
Our results demonstrate that SqCCs have a significantly higher rate of local failure after SBRT than do other NSCLCs. The local failure rate for SqCCs was twofold higher than for adenocarcinomas. The 3-year cumulative incidence of local failure for SqCCs was approximately 19%. For patients receiving the most frequent regimen of 50 Gy in five fractions, the cumulative rate of failure was approximately 25%. These results suggest that SqCCs are more resistant to SBRT than other NSCLCs are. The clinically significant implication of our study is that SBRT treatments should be optimized on the basis of histological subtype.
Our study's 3-year local tumor control rate of 88.2% is comparable to published values. [2] [3] [4] 29 The strengths of this study include the large number of patients evaluated, the homogeneity of treatment delivery, the extent of pathologic confirmation of NSCLCs, the length and extent of radiographic followup, and the completeness of the data set. Although we addressed possible confounding factors in our analyses, we cannot fully account for all potential causes of bias. For example, a selection bias could have favored adenocarcinomas because they can be more likely to be peripheral and able to receive the higher BED of radiation of 180 Gy. However, we did not find any evidence to that effect. There was no statistical difference in the proportion of central to peripheral tumors or in the dose of radiation between adenocarcinomas and SqCCs (see Table 1 ), and central tumors were not significantly more likely to experience local failure than peripherally located tumors (see Table 3 ). This study is the first demonstration of a histological basis for local failure after SBRT. Previous prospective and retrospective data have not identified differential local failure rates for SqCCs compared with for other NSCLCs. 32, [36] [37] [38] [39] [40] Putative explanations include the smaller number of patients evaluated, insufficient pathologic confirmation of disease, a low proportion of SqCCs, and the apparent lack of evaluation of histological subtype as a predictor of failure in those studies. In our study, 215 patients (29%) had a confirmed diagnosis of SqCC, which to our knowledge makes our study one of the largest studies of SqCCs treated with SBRT to date. Several questions remain to be answered. First, why SqCCs are more likely to fail SBRT than adenocarcinomas is unclear. Genetic and/or microenviromental features may account for some of these differences. For example, SqCCs have distinct patterns of somatic alterations, a propensity for a higher mutational burden, and a higher metabolic rate resulting in hypoxia; some or all of these features may contribute to radioresistance. [41] [42] [43] Second, it is unclear why a subset of SqCCs fail SBRT. Comparative genomic evaluation of SqCCs that fail and those that do not may help elucidate the precise regulators of resistance and guide the selective reversal of that resistance by targeted therapies. Third, it appears that higher doses of radiation may reduce the probability of failure after SBRT. However, dose escalation needs to be balanced against toxicity, especially for central tumors located in close proximity to organs at risk. 31 Alternative fractionation and dose schemes that increase BED while minimizing acute and delayed toxicity may optimize local control in cases in which toxicity is a concern.
In conclusion, although highly effective in a diverse population of NSCLCs, SBRT can result in an unacceptably high local failure rate in patients with SqCCs. These findings should help motivate an evolution of SBRT from a generic population-based approach toward more nuanced patient selection and treatments. A B Figure 3 . Estimated cumulative incidence curves with overall mortality and local failure as competing events for adenocarcinoma (Adeno) and squamous cell carcinoma (SqCC) for patients receiving a biologically effective dose (BED) of 100 Gy (A) and 180 Gy (B). Death is represented in solid lines. Local failure is represented in dashed lines.
